Ryan Maynard
2022
In 2022, Ryan Maynard earned a total compensation of $1.9M as Chief Financial Officer at Cara Therapeutics.
Compensation breakdown
| Bonus | $8,312 |
|---|---|
| Non-Equity Incentive Plan | $38,788 |
| Option Awards | $1,701,405 |
| Salary | $140,600 |
| Other | $197 |
| Total | $1,889,302 |
Maynard received $1.7M in option awards, accounting for 90% of the total pay in 2022.
Maynard also received $8.3K in bonus, $38.8K in non-equity incentive plan, $140.6K in salary and $197 in other compensation.
Rankings
In 2022, Ryan Maynard's compensation ranked 1,855th out of 5,756 executives tracked by ExecPay. In other words, Maynard earned more than 67.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,855 out of 5,756 | 68th |
Division Manufacturing | 974 out of 3,133 | 69th |
Major group Chemicals And Allied Products | 403 out of 1,419 | 72nd |
Industry group Drugs | 368 out of 1,320 | 72nd |
Industry Pharmaceutical Preparations | 264 out of 966 | 73rd |
Source: SEC filing on April 20, 2023.
Maynard's colleagues
We found two more compensation records of executives who worked with Ryan Maynard at Cara Therapeutics in 2022.